Securities Code: 002390 Securities Abbreviation: Xinbang Pharmaceutical Announcement No.: 2026-006 Guizhou Xinbang Pharmaceutical Co., Ltd. Announcement on the 2025 Profit Distribution Pre-proposal The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions. Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") deliberated and approved the "2025 Profit Distribution Pre-proposal" at the 10th meeting of the 9th Board of Directors held on April 17, 2026. The relevant matters are hereby announced as follows: I. Deliberation Procedures (I) Board of Directors Deliberation The Company's 9th Board of Directors, at its 10th meeting held on April 17, 2026, deliberated and approved the "2025 Profit Distribution Pre-proposal" with 8 votes in favor, 0 votes against, and 0 abstentions. (II) Shareholders' Meeting Deliberation This profit distribution pre-proposal needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation. II. Basic Information of the Profit Distribution Pre-proposal (I) Basic Content of this Profit Distribution Pre-proposal
- Distribution Basis: 2025.
- According to the audit by Beijing Dehao International Certified Public Accountants (Special General Partnership), the Company's net profit in 2025 was RMB 191,795,599.53, of which the net profit attributable to shareholders of the listed company was RMB 120,285,770.05; the net profit realized by the parent company in 2025 was RMB 428,375,115.93. In accordance with the "Company Law" and the "Articles of Association," the Company, after deducting 10% of the net profit for the year to statutory surplus reserve, which amounted to RMB 42,837,511.59, had distributable profits of RMB 420,416,165.71 in the consolidated statements as of December 31, 2025, and distributable profits of RMB 339,857,443.66 for the parent company.
- Share Capital Base: The base is the total share capital of the Company of 1,943,851,868 shares, minus the 47,445,540 shares repurchased by the Company's dedicated securities account for repurchases, totaling 1,896,406,328 shares.
- Based on the total share capital of the Company of 1,943,851,868 shares, minus the 47,445,540 shares repurchased by the Company's dedicated securit